ReviewClinical, cosmetic and investigational dermatology2026
Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic recurrent inflammatory disease driven by keratinocytes and immune cells. Exosomes, as key mediators of intercellular communication, play multidimensional roles in this disease. In terms of pathogenic mechanisms, exosomes released from psoriatic lesions carry non‑coding RNAs and proteins that program T‑cell polarization, drive M1 macrophage activation, and amplify keratinocyte inflammation, thereby sustaining the IL‑23/Th17 immune axis. Translational breakthroughs have repurposed these same vesicles into diagnostic and therapeutic tools. Circulating exosomal fingerprints offer non‑invasive biomarkers for disease activity and psoriatic arthritis differentiation. Leveraging their biocompatibility and low immunogenicity, exosomes from mesenchymal stem cells, plants, and microbes serve as cell‑free platforms achieving immune regulation, antioxidant effects, and microecological repair. Engineering strategies-including cargo loading, membrane surface modification and intelligent microneedle delivery systems-further enhance targeting and efficacy. Despite these advances, clinical translation faces fundamental challenges: lack of production standardization, undefined core active components and insufficient high‑level clinical evidence. Future efforts should prioritize international standards, rational design, and rigorous trials to accelerate exosome‑based precision medicine for psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.